focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 333.00
Bid: 333.00
Ask: 337.00
Change: -7.00 (-2.06%)
Spread: 4.00 (1.201%)
Open: 335.00
High: 336.00
Low: 329.00
Prev. Close: 340.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Chi-Med to Attend Upcoming Investor Conferences

11 May 2020 07:00

RNS Number : 3486M
Hutchison China Meditech Limited
11 May 2020
 

Press Release

Chi-Med to Attend Upcoming Investor Conferences

London: Friday, May 11, 2020: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) today announces that Mr Christian Hogg, Chief Executive Officer of Chi-Med, will participate in a virtual fireside chat at the Bank of America 2020 Health Care Conference on Thursday, May 14, 2020 9:40 a.m. Eastern Daylight Time (EDT).

 

The discussion will be webcast live and can be accessed at www.chi-med.com in the Shareholder Information section under "Events, Circulars & Forms." Investors interested in listening to the live webcast should log on before the start time to download any software required. A replay of the event will be available shortly thereafter for approximately 90 days.

 

Members of the senior management team will also attend virtual one-on-one meetings at the Bank of America Health Care Conference on May 14, as well as during the following other conferences:

 

· Citi Virtual Pan-Asia Regional Investor Conference from Tuesday to Thursday, May 19 to 21, 2020;

 

· Jefferies Virtual Global Healthcare Conference from Tuesday to Thursday, June 2 to 4, 2020; and

 

· Goldman Sachs Global Healthcare Conference Webcast from Tuesday to Thursday, June 9 to 11, 2020.

 

About Chi-Med

Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com.

 

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med's filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

 

CONTACTS

Investor Enquiries

Mark Lee, Senior Vice President

+852 2121 8200

Annie Cheng, Vice President

+1 (973) 567 3786

Media Enquiries

 

Americas - Brad Miles, Solebury Trout

+1 (917) 570 7340 (Mobile) bmiles@troutgroup.com

Europe - Ben Atwell / Alex Shaw, FTI Consulting

+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)Chi-Med@fticonsulting.com

Asia - Joseph Chi Lo / Zhou Yi, Brunswick

+852 9850 5033 (Mobile), jlo@brunswickgroup.com / +852 9783 6894 (Mobile), yzhou@brunswickgroup.com

Nominated Advisor

Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited

+44 (20) 7886 2500

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAMZGGKRRZGGZG
Date   Source Headline
9th Oct 20137:00 amRNSAnalyst & Investor Briefing
3rd Oct 20137:00 amRNSAnalyst briefing on Chi-Med's R&D business
13th Sep 20132:21 pmRNSHolding(s) in Company
8th Aug 201312:05 pmRNSDirector/PDMR Shareholding
30th Jul 20137:00 amRNSInterim Results
17th Jul 20137:00 amRNSGlobal Phase III HPML-004 maintenance study starts
1st Jul 20137:00 amRNSBlocklisting Interim Review
25th Jun 20137:00 amRNSVolitinib Phase I triggers US$5 million milestone
24th Jun 20137:00 amRNSNotice of Results
10th May 201312:24 pmRNSResult of AGM
24th Apr 20137:00 amRNSGlobal Phase III UC trial initiated with HPML-004
12th Apr 20137:16 amRNSNutrition Science Partners JV Approved
9th Apr 20137:00 amRNS2012 Annual Report and Notice of AGM
8th Apr 20137:00 amRNSData Presentations at AACR
26th Mar 20137:00 amRNSFinal Results
28th Feb 20137:00 amRNSTotal Voting Rights
18th Feb 20137:00 amRNSNotice of Results
28th Jan 201311:15 amRNSHolding(s) in Company
31st Dec 20127:00 amRNSBlocklisting Six Monthly Return
28th Nov 20127:00 amRNSChi-Med and Nestle´ Health Science Joint Venture
1st Nov 20127:00 amRNSPhase I trial with EGFR inhibitor theliatinib
8th Oct 20127:00 amRNSTR1 Notification of major interest in shares
28th Sep 20121:42 pmRNSTotal Voting Rights
13th Sep 20122:16 pmRNSDirector's Shareholding
28th Aug 201211:21 amRNSChange of Nominated Adviser
31st Jul 20127:00 amRNSInterim Results
5th Jul 20129:08 amRNSTotal Voting Rights
29th Jun 20127:00 amRNSBlocklisting Interim Review
28th Jun 20127:00 amRNSNotice of Results
14th Jun 20121:33 pmRNSExercise of Options
6th Jun 20127:00 amRNSAnti-Cancer Clinical Data Presented at ASCO
30th May 20121:48 pmRNSDirector/PDMR Shareholding
11th May 201212:32 pmRNSResult of AGM
10th Apr 20127:00 amRNS2011 Annual Report and Notice of AGM
20th Mar 20127:00 amRNSFinal Results
22nd Feb 20127:00 amRNSNovel c-Met inhibitor Volitinib Enters the Clinic
20th Feb 20127:00 amRNSNotice of Results
14th Feb 20128:07 amRNSHolding(s) in Company
2nd Feb 20127:00 amRNSTotal Voting Rights
5th Jan 201210:49 amRNSHolding(s) in Company
29th Dec 20117:00 amRNSBlocklisting Six Monthly Return
21st Dec 20117:00 amRNSCANCER THERAPY COLLABORATION WITH ASTRAZENECA
12th Dec 20117:00 amRNSChi-Med Loan Facility
4th Nov 20117:00 amRNSInitiates Epitinib Phase I clinical study
5th Sep 20117:00 amRNSHolding(s) in Company
1st Aug 20117:00 amRNSInterim Results
22nd Jul 20117:00 amRNSChina Healthcare Division expansion
5th Jul 20117:00 amRNSNotice of Results
29th Jun 20117:00 amRNSBlocklisting Interim Review
13th May 20118:25 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.